DOI: https://doi.org/10.22141/2307-1257.4.18.2016.84320

Pharmacogenetic Tests in the Nephrological Clinic

D.D. Ivanov, O.O. Melnik

Abstract


Selection of antihypertensive agents using pharmacogenetic tests and individual tolerance is essential in practical nephrology. Antihypertensive first-line drugs are metabolized through various CYP isoforms (CYP2D6, CYP2C9, CYP2C19 and CYP3A4/5). These isoforms are the most significant for the patient in response to the drug. From a clinical point of view, it is important to establish the slow metabolizers, because in them we should use other doses of antihypertensive drugs that differ from the standard ones.

Keywords


antihypertensive drugs in nephrology; pharmacogenetic tests; CYP isoforms (CYP2D6; CYP2C9; CYP2C19;­CYP3A4/5); titration of the drug

References


Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease // Kidney inter. — 2013. — ​Suppl. 3. — ​Р. 1-150.

Grassi G Sympathetic overdrive in hypertension: clinical and therapeutic relevance // The e-journal of the ESC Council for Cardio­logy Practice. — 24 Nov 2015. — ​Vol. 13, № 36.

Ivanov D. Почки. Нирки. Kidneys. — 2016. — № 1(16). — ​Р. 16.

Turner S.T., Schwartz G.L., Chapman A.B. et al. Antihypertensive pharmacogenetics: getting the right drug into the right patient // J. Hypertension. — 2001. — № 19. — ​Р. 1-11.

Cacabelos R. The Metabolomic Paradigm of Pharmacogeno­mics in Complex Disorders // Metabolomics. — 2012. — № 2. — ​e119.

International Consortium for Blood Pressure Genome-Wide Association Studies et al, Genetic variants in novel pathways infl uence blood pressure and cardiovascular disease risk // Nature. — 2011. — ​V. 478. — ​P. 103-9.

Schwartz G.L., Turner S.T. Pharmacogenetics of antihypertensive drug responses // Am. J. Pharmacogenomics. — 2004. — № 4. — ​Р. 151-160.

Kirchheiner J., Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes // Biochim. Biophys. Acta. — 2007. — № 1770. — ​Р. 489-494.

Flockhart D.A., Tanus-Santos J.E. Implications of cytochrome P450 interactions when prescribing medication for hypertension // Arch. Intern. Med. — 2002. — № 162. — ​Р. 405-412.

Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future // Trends Pharmacol. Sci. — 2004. — № 25. — ​Р. 193-200.

Kreutz R. Pharmacogenetics of antihypertensive drug response // Curr. Hypertens. Rep. — 2004. — № 6. — ​Р. 15-20.

Cacabelos R. World guide for drug use and pharmacogeno­mics. — EuroEspes Publishing, Corunna, 2012.

Höcht C., Bertera F.M., Mayer M.A., Taira C.A. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers // Expert Opin. Drug Metab. Toxicol. — 2010. — № 6(2). — ​Р. 199-211.

Siest G., Jeannesson E., Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs // Clin. Chim. Acta. — 2007. — № 381. — ​Р. 26-31.

Rodríguez Arcas M.J., García-Jiménez E., Martínez-Martínez F., Conesa-Zamora P. Role of CYP450 in pharmacokinetics and pharmacogenetics of antihypertensive drugs // Farm. Hosp. — 2011. — № 35. — ​Р. 84-92.

Torrellas C., Carril J.C., Cacabelos R. Benefits of Pharmacogenetics in the Management of Hypertension // J. Pharmacogeno­mics & Pharmacoproteomics. — 2014. — № 5. — ​Р. 1-7.

http://www.health-medix.com/articles/misteztvo/2009-03-24/7-14.pdf

Polimanti R., Iorio A., Piacentini S. et al. Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine // Pharmacogenomics. — 2014. — № 15(2). — ​Р. 157-67.






Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта